The pre-treatment CD34+/CD38- cell burden as prognostic factor in MDS patients receiving allogeneic stem cell transplantation

Myelodysplastic Syndromes (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are heterogeneous clonal hematopoietic disorders resulting in inefficient hematopoiesis and a variable progression risk to secondary acute myeloid leukemia (AML).1-3 At diagnosis, the international prognostic scoring system (IPSS)1 and the revised international prognostic scoring system (IPSS-R)2 are commonly used to estimate disease aggressiveness for subsequent therapeutic decision making. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment option for MDS patients and is of particular interest in high-risk disease.

Source: Biology of Blood and Marrow Transplantation - March 27, 2019 Category: Hematology Authors: Dr. Madlen Jentzsch, Ulrike Geus, Juliane Grimm, Dr. Vladan Vucinic, Dr. Wolfram P önisch, Dr. Georg-Nikolaus Franke, Prof. Dr. Gerhard Behre, Prof. Dr. Dietger Niederwieser, PD Dr. Sebastian Schwind Source Type: research